TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis

Niklas Finnberg1, Andres J P Klein-Szanto, Wafik S El-Deiry

  • 1Laboratory of Molecular Oncology and Cell Cycle Regulation, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.

Insights

The TNF-related apoptosis-inducing ligand receptor (TRAIL-R) acts as a crucial tumor suppressor. Loss of TRAIL-R in mice led to increased tumor development, metastasis, and reduced survival, highlighting its role in preventing cancer.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Preclinical studies suggest TRAIL death-signaling receptors are potential cancer therapy targets.
  • The in vivo role of these receptors in suppressing tumor emergence and growth remains unclear.

Purpose of the Study:

  • To investigate the function of TNF-related apoptosis-inducing ligand receptor (TRAIL-R) as a tumor suppressor in vivo.
  • To determine if TRAIL-R deficiency impacts lymphoma development, metastasis, and response to radiation or chemical carcinogens.

Main Methods:

  • Utilized Emu-myc mice with TRAIL-R allele loss to study lymphoma development.
  • Assessed survival and tumor formation in TRAIL-R knockout mice after sublethal irradiation and diethylnitrosamine (DEN) treatment.
  • Histological analysis and NF-kappaB p65 expression were evaluated.

Main Results:

  • Loss of TRAIL-R significantly reduced lymphoma-free survival and increased metastatic potential.
  • TRAIL-R deficiency led to apoptotic defects in lymphomas and decreased survival after irradiation.
  • TRAIL-R knockout mice exhibited increased susceptibility to DEN-induced hepatocarcinogenesis with larger tumors and apoptotic defects.

Conclusions:

  • TRAIL-R functions as an in vivo suppressor of inflammation and tumor development.
  • TRAIL-R deficiency promotes tumorigenesis and metastasis across multiple tissues.
  • TRAIL-R is a critical regulator of apoptosis and immune response in cancer suppression.

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...